Business / Finance

RSS

Biogen acquires TYSABRI stake from Elan

Biogen Idec today announced it has completed its purchase of Elan Corporation's interest in TYSABRI (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI.

3 Apr 2013

Microbiology testing services now offered by Ceram

Ceram, the international materials testing and development company, has announced that it is now offering microbiology testing services for the healthcare industries, thanks to a partnership with a leading UK microbiological testing lab.

2 Apr 2013

Revance Therapeutics raises $33M in Series E financing

Revance Therapeutics, Inc., a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aesthetic and therapeutic indications, today announced that it has raised $33 million of its Series E growth financing.

2 Apr 2013

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.

From Chromatrap® - Porvair Sciences Ltd 28 Mar 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Clinigen announces acquisition of Cardioxane from Novartis

Clinigen Group plc today announced the acquisition of Cardioxane (dexrazoxane) from Novartis for US$33 million in cash, payable in two tranches.

From Clinigen Group 26 Mar 2013

European mobile health market to reach €2.45 billion in 2016

The European mobile health market forecasts strikingly high growth rates in coming years, despite the global financial crisis. Frost & Sullivan expects the market to grow from €393 million in 2011 to €2.45 billion in 2016 therefore, creating vast opportunities for industry players.

19 Mar 2013

AGA, CDC partner to promote free colonoscopies for uninsured patients

Colorectal cancer (CRC) is the second leading cause of cancer deaths among men and women nationwide. During National Colorectal Cancer Awareness Month, the Centers for Disease Control and Prevention (CDC) and the American Gastroenterological Association (AGA) are joining forces for the second year to promote free colonoscopies for uninsured patients.

19 Mar 2013

Luminex collaborates with Merck to design companion diagnostic device for Alzheimer’s disease

WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

From Luminex 15 Mar 2013

Business Network Services to be launched by Anglia Ruskin MedTech Campus

Companies from across the medical technology sector will be offered improved access to the NHS and global markets when the Anglia Ruskin MedTech Campus launches its Business Network Services on Wednesday, 13 March.

7 Mar 2013

IMRIS fourth quarter total revenues increase 37% to $20.1 million

IMRIS Inc. today reported its results for the fourth quarter and full year of 2012. All figures are reported in US dollars.

5 Mar 2013

Avedro announces completion of $43M Series D financing

Avedro, Inc. announced today the completion of a $43 million Series D financing led by Abingworth along with a significant investment by Third Point.

5 Mar 2013

Acadia proposes $150M in senior unsecured notes due 2021

Acadia Healthcare Company, Inc. today announced that it is proposing to issue $150 million in senior unsecured notes due 2021 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended.

5 Mar 2013

WomanCare Global, Evofem enter strategic alliance

Evofem announced today that it has entered into a strategic alliance with WomanCare Global. Through this alliance, WomanCare Global will provide sales, marketing and global distribution for a selection of Evofem's products, including Softcup and Amphora.

4 Mar 2013

OPKO Health acquires Cytochroma

OPKO Health, Inc. announced that it has completed the acquisition of Cytochroma Inc. Cytochroma's lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in CKD patients on chronic hemodialysis.

4 Mar 2013